Eloxx Pharmaceuticals Inc ELOX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELOX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.79
- Day Range
- $0.75–0.83
- 52-Week Range
- $0.40–10.90
- Bid/Ask
- $0.75 / $0.87
- Market Cap
- $2.53 Mil
- Volume/Avg
- 1,885 / 7,727
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company's investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 18
- Website
- https://www.eloxxpharma.com
Valuation
|
Metric
|
ELOX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELOX
|
|---|---|
Quick Ratio | 0.20 |
Current Ratio | 0.24 |
Interest Coverage | −12.63 |
Quick Ratio
ELOX
Profitability
|
Metric
|
ELOX
|
|---|---|
Return on Assets (Normalized) | −136.52% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ELOX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zqmmrvwgb | Nkl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ynxqyqj | Qbrlh | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xcdxxqj | Zxjdp | $97.8 Bil | |
MRNA
| Moderna Inc | Lszhpym | Spds | $41.3 Bil | |
ARGX
| argenx SE ADR | Yykybzkc | Wnx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Dyzqbzd | Zqcpm | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Grhfrwtsx | Wbpbvdy | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xxdmcfhc | Gplrzh | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zqgpkpckj | Blgdlmg | $12.5 Bil | |
INCY
| Incyte Corp | Zqryqvzgj | Fhtcvy | $11.6 Bil |